K. Haglund

522 total citations
24 papers, 361 citations indexed

About

K. Haglund is a scholar working on Cardiology and Cardiovascular Medicine, Analytical Chemistry and Molecular Biology. According to data from OpenAlex, K. Haglund has authored 24 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cardiology and Cardiovascular Medicine, 8 papers in Analytical Chemistry and 5 papers in Molecular Biology. Recurrent topics in K. Haglund's work include Analytical Methods in Pharmaceuticals (8 papers), Blood Pressure and Hypertension Studies (7 papers) and Computational Drug Discovery Methods (4 papers). K. Haglund is often cited by papers focused on Analytical Methods in Pharmaceuticals (8 papers), Blood Pressure and Hypertension Studies (7 papers) and Computational Drug Discovery Methods (4 papers). K. Haglund collaborates with scholars based in Sweden, United Kingdom and Austria. K. Haglund's co-authors include P. Collste, Christer von Bahr, Peter Seideman, Marianne Frisk‐Holmberg, C G Regårdh, B. Edgar, M. D. Rawlins, Björn Lindström, J. �stman and Michael Orme and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Drugs and British Journal of Clinical Pharmacology.

In The Last Decade

K. Haglund

24 papers receiving 299 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Haglund Sweden 13 147 59 58 57 54 24 361
DJ Sumner United Kingdom 11 138 0.9× 84 1.4× 42 0.7× 54 0.9× 64 1.2× 14 357
JC Petrie United Kingdom 12 189 1.3× 45 0.8× 61 1.1× 66 1.2× 45 0.8× 28 373
G. Bodem Germany 13 139 0.9× 61 1.0× 49 0.8× 79 1.4× 95 1.8× 47 463
J C Petrie United Kingdom 14 179 1.2× 39 0.7× 62 1.1× 68 1.2× 41 0.8× 32 448
Kandace M. Matzek United States 6 184 1.3× 67 1.1× 83 1.4× 37 0.6× 64 1.2× 10 489
K. Reiff United States 9 187 1.3× 130 2.2× 66 1.1× 66 1.2× 59 1.1× 16 515
Klaus D. Raemsch Germany 6 90 0.6× 71 1.2× 53 0.9× 54 0.9× 61 1.1× 8 376
AK Scott United Kingdom 15 171 1.2× 48 0.8× 38 0.7× 62 1.1× 62 1.1× 26 539
Yin‐Gail Yee United States 12 217 1.5× 96 1.6× 57 1.0× 73 1.3× 77 1.4× 16 510
Leonard Gonasun United States 15 137 0.9× 62 1.1× 57 1.0× 67 1.2× 82 1.5× 23 495

Countries citing papers authored by K. Haglund

Since Specialization
Citations

This map shows the geographic impact of K. Haglund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Haglund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Haglund more than expected).

Fields of papers citing papers by K. Haglund

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Haglund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Haglund. The network helps show where K. Haglund may publish in the future.

Co-authorship network of co-authors of K. Haglund

This figure shows the co-authorship network connecting the top 25 collaborators of K. Haglund. A scholar is included among the top collaborators of K. Haglund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Haglund. K. Haglund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wettermark, Björn, et al.. (2005). A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists. Pharmacoepidemiology and Drug Safety. 14(8). 579–588. 13 indexed citations
2.
Haglund, K., et al.. (1988). Cadralazine pharmacokinetics ? A pilot study. European Journal of Clinical Pharmacology. 35(5). 571–572. 2 indexed citations
3.
Lithell, Hans, K. Haglund, Fredrik Granath, & Jan Östman. (1988). Are Effects of Antihypertensive Treatment on Lipoproteins Merely “Side‐effects”?. Acta Medica Scandinavica. 223(6). 531–536. 3 indexed citations
4.
Sjoden, Glenn, et al.. (1987). Calcium absorption and excretion in patients treated with verapamil.. British Journal of Clinical Pharmacology. 24(3). 367–371. 7 indexed citations
5.
Edgar, B., P. Collste, K. Haglund, & C G Regårdh. (1987). Pharmacokinetics and Haemodynamics of Felodipine as Monotherapy in Hypertensive Patients. Drugs. 34(Supplement 3). 28–29. 6 indexed citations
6.
Edgar, B., P. Collste, K. Haglund, & C G Regårdh. (1987). Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients.. PubMed. 10(5). 388–94. 42 indexed citations
7.
Seideman, Peter, et al.. (1987). Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.. British Journal of Clinical Pharmacology. 23(3). 267–271. 5 indexed citations
8.
Wahrenberg, Hans, Peter Arner, Peter Engfeldt, et al.. (1985). Long‐term β1‐Selective Adrenergic Blockade and Adrenergic Receptors in Human Subcutaneous Adipocytes. Acta Medica Scandinavica. 217(5). 539–546. 9 indexed citations
9.
Andersson, O, C. Bengtsson, Dag Elmfeldt, et al.. (1984). Short‐term effects of felodipine, a new dihydropyridine, in hypertension.. British Journal of Clinical Pharmacology. 17(3). 257–263. 27 indexed citations
10.
Seideman, Peter, A. Grahnén, K. Haglund, B. Lindström, & Christer von Bahr. (1982). Prazosin first dose phenomenon during combined treatment with a beta‐ adrenoceptor blocker in hypertensive patients.. British Journal of Clinical Pharmacology. 13(6). 865–870. 14 indexed citations
11.
Östman, Jan, Peter Arner, K. Haglund, et al.. (1982). Effect of Metoprolol and Alprenolol on the Metabolic, Hormonal, and Haemodynamic Response to Insulin‐Induced Hypoglycaemia in Hypertensive, Insulin‐Dependent Diabetics. Acta Medica Scandinavica. 211(5). 381–385. 8 indexed citations
12.
Collste, P., K. Haglund, & Christer von Bahr. (1980). Plasma levels and effects of metoprolol after single and multiple oral doses. Clinical Pharmacology & Therapeutics. 27(4). 441–449. 16 indexed citations
13.
Seideman, Peter, Leif Bertilsson, K. Haglund, et al.. (1980). Monoamine metabolites in cerebrospinal fluid during treatment of hypertension with prazosin. European Journal of Clinical Pharmacology. 18(5). 399–401. 4 indexed citations
14.
Haglund, K. & P. Collste. (1980). Time course of blood pressure, pulse rate, plasma renin and metoprolol during treatment of hypertensive patients. European Journal of Clinical Pharmacology. 17(5). 321–328. 6 indexed citations
15.
Collste, P., et al.. (1979). Influence of pentobarbital on effect and plasma levels of alprenolol and 4‐hydroxy‐alprenolol. Clinical Pharmacology & Therapeutics. 25(4). 423–427. 12 indexed citations
16.
Haglund, K., et al.. (1979). Influence of pentobarbital on metoprolol plasma levels. Clinical Pharmacology & Therapeutics. 26(3). 326–329. 12 indexed citations
17.
Bertilsson, Leif, K. Haglund, J. �stman, et al.. (1977). Monoamine metabolites in cerebrospinal fluid during treatment with clonidine or alprenolol. European Journal of Clinical Pharmacology. 11(2). 125–128. 23 indexed citations
18.
Collste, P., K. Haglund, Marianne Frisk‐Holmberg, & M. D. Rawlins. (1976). Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. European Journal of Clinical Pharmacology. 10(2). 85–88. 15 indexed citations
19.
Collste, P., K. Haglund, Marianne Frisk‐Holmberg, et al.. (1976). Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. European Journal of Clinical Pharmacology. 10(2). 89–95. 22 indexed citations
20.
Collste, P., et al.. (1976). Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension. Clinical Pharmacology & Therapeutics. 20(2). 130–137. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by DJ Sumner Breakdown of academic impact, for papers by JC Petrie Breakdown of academic impact, for papers by G. Bodem Breakdown of academic impact, for papers by J C Petrie Breakdown of academic impact, for papers by Kandace M. Matzek Breakdown of academic impact, for papers by K. Reiff Breakdown of academic impact, for papers by Klaus D. Raemsch Breakdown of academic impact, for papers by AK Scott Breakdown of academic impact, for papers by Yin‐Gail Yee Breakdown of academic impact, for papers by Leonard Gonasun
Rankless by CCL
2026